Inotek Pharmaceuticals (ITEK) announced that it has initiated a Phase 2 dose-ranging study of a fixed-dose combination of trabodenoson and latanoprost in an eye-drop formulation for the treatment of glaucoma. The 165-subject study will randomize patients with ocular hypertension or primary open-angle glaucoma who have intraocular pressure (IOP) of at least 25 mmHg to receive one of three combinations of the drugs or one of two separate concentrations of latanoprost alone. The primary endpoint is mean IOP at month 2.